Nasdaq · CIK 0001228627
IRD Opus Genetics, Inc.
Insider trading from SEC Form 4. Last filing 11 d ago. Close $4.65 on Oct 9, 2026, +167% from the 52-week low and -23% from the high.
Opus Genetics, Inc. (IRD) has 64 SEC Form 4 filings on file from 13 insiders, the latest filed on Oct 2, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 2 open-market sells worth $2.9M, net -$2.9M.
15 open-market trades have been scored at IRD. The newest: Foundation Fighting Blindness Retinal Degeneration Fund (director) sold $2.8M of stock on Sep 30, 2026, filed Oct 2, 2026, scored 45 (moderate). The largest of the 15 shown: Foundation Fighting Blindness Retinal Degeneration Fund (director) sold $8.6M on Dec 9, 2025, scored 50 (moderate). 3 insiders sold within 14 days of each other around Apr 23, 2026.
IRD closed at $4.65 on Oct 9, 2026, 167% above its 52-week low and 23% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Opus Genetics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Foundation Fighting Blindness Retinal Degeneration Fund director, other sell | $2.8M 556,000 shares | -15% | +193% from low-20% from high | |
| 13Weak | Robert E. Gagnon Chief Financial Officer sell | $127k 28,000 shares | -5% | - | |
| 50Moderate | Foundation Fighting Blindness Retinal Degeneration Fund director, other sell | $7.4M 1,700,000 shares | -31% | +388% from low-23% from high | |
| 43Moderate | Robert E. Gagnon Chief Financial Officer sell | $41k 7,842 shares | -1% | +586% from low-9% from high | |
| 36Weak | Ashwath Jayagopal Chief Scientific & Dev. Ofc. sell | $39k 7,542 shares | -1% | +586% from low-9% from high | |
| 47Moderate | George Magrath Chief Executive Officer sell | $50k 9,511 shares | -1% | +586% from low-9% from high | |
| 30Weak | Ashwath Jayagopal Chief Scientific & Dev. Ofc. sell | $19k 3,719 shares | -1% | +631% from low0% from high | |
| 51Moderate | George Magrath Chief Executive Officer sell | $127k 24,438 shares | -1% | +631% from low0% from high | |
| 30Weak | Rabourn Amy Zaremba Head of Fin. Quality Assurance sell | $15k 2,816 shares | -1% | +631% from low0% from high | |
| 35Weak | Joseph K Schachle Chief Operating Officer sell | $20k 3,719 shares | -1% | +631% from low0% from high | |
| 36Weak | Cam Gallagher director buy | $324k 164,000 shares | +9% | +180% from low-20% from high | |
| 50Moderate | Foundation Fighting Blindness Retinal Degeneration Fund director, other sell | $8.6M 4,000,000 shares | -42% | +237% from low0% from high | |
| 46Moderate | George Magrath Chief Executive Officer buy | $98k 100,000 shares | +20% | - | |
| 28Weak | Benjamin R Yerxa President buy | $9,834 10,000 shares | +3% | - | |
| 49Moderate | George Magrath Chief Executive Officer buy | $101k 100,000 shares | +25% | - |
Transactions
The newest 50 of 84 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Foundation Fighting Blindness Retinal Degeneration Fund director, other | SOpen-market sale Common Stock | -556,000 | $4.96 | $2.8M | 3,236,171 | 11 d ago |
| Sep 9, 2026 | George Magrath Chief Executive Officer | MOption exercise Common Stock | +392,157 | $1.15 | $451k | 2,124,026 | 32 d ago |
| Sep 9, 2026 | George Magrath Chief Executive Officer | FTax withholding Common Stock | -75,541 | $5.97 | $451k | 2,048,485 | 32 d ago |
| Sep 9, 2026 | George Magrath Chief Executive Officer | MOption exercise Warrant (right to buy)derivative | -392,157 | $0.00 | $0 | 0 | 32 d ago |
| Sep 8, 2026 | Cam Gallagher director | MOption exercise Common Stock | +784,314 | $1.15 | $902k | 2,800,111 | 35 d ago |
| Sep 3, 2026 | Robert E. Gagnon Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -28,000 | $4.54 | $127k | 556,375 | 35 d ago |
| Sep 8, 2026 | Cam Gallagher director | MOption exercise Warrant (right to buy)derivative | -784,314 | $0.00 | $0 | 0 | 35 d ago |
| May 18, 2026 | Foundation Fighting Blindness Retinal Degeneration Fund director, other | SOpen-market sale Common Stock | -1,700,000 | $4.35 | $7.4M | 3,792,171 | May 20, 2026 |
| Apr 23, 2026 | Robert E. Gagnon Chief Financial Officer | SOpen-market sale Common Stock | -7,842 | $5.18 | $41k | 592,158 | Apr 27, 2026 |
| Apr 23, 2026 | Ashwath Jayagopal Chief Scientific & Dev. Ofc. | SOpen-market sale Common Stock | -7,542 | $5.19 | $39k | 509,233 | Apr 27, 2026 |
| Apr 23, 2026 | George Magrath Chief Executive Officer | SOpen-market sale Common Stock | -9,511 | $5.22 | $50k | 1,741,344 | Apr 27, 2026 |
| Apr 20, 2026 | Adrienne L Graves director | AGrant or award Common Stock | +24,367 | $0.00 | $0 | 127,514 | Apr 22, 2026 |
| Apr 20, 2026 | James S J Manuso director | AGrant or award Common Stock | +24,367 | $0.00 | $0 | 317,318 | Apr 22, 2026 |
| Apr 20, 2026 | Sean Ainsworth director | AGrant or award Common Stock | +24,367 | $0.00 | $0 | 321,692 | Apr 22, 2026 |
| Apr 20, 2026 | Jean Bennett director | AGrant or award Common Stock | +24,367 | $0.00 | $0 | 259,019 | Apr 22, 2026 |
| Apr 20, 2026 | Susan Benton director | AGrant or award Common Stock | +24,367 | $0.00 | $0 | 243,894 | Apr 22, 2026 |
| Apr 20, 2026 | Cam Gallagher director | AGrant or award Common Stock | +24,367 | $0.00 | $0 | 2,015,797 | Apr 22, 2026 |
| Mar 16, 2026 | Ashwath Jayagopal Chief Scientific & Dev. Ofc. | SOpen-market sale Common Stock | -3,719 | $5.12 | $19k | 516,775 | Mar 18, 2026 |
| Mar 16, 2026 | George Magrath Chief Executive Officer | SOpen-market sale Common Stock | -24,438 | $5.21 | $127k | 1,750,855 | Mar 18, 2026 |
| Mar 16, 2026 | Rabourn Amy Zaremba Head of Fin. Quality Assurance | SOpen-market sale Common Stock | -2,816 | $5.25 | $15k | 190,312 | Mar 18, 2026 |
| Mar 16, 2026 | Joseph K Schachle Chief Operating Officer | SOpen-market sale Common Stock | -3,719 | $5.25 | $20k | 300,781 | Mar 18, 2026 |
| Feb 12, 2026 | Ashwath Jayagopal Chief Scientific & Dev. Ofc. | FTax withholding Common Stock | -5,313 | $3.39 | $18k | 520,494 | Feb 17, 2026 |
| Jan 22, 2026 | Robert E. Gagnon Chief Financial Officer | AGrant or award Common Stock | +400,000 | $0.00 | $0 | 600,000 | Jan 26, 2026 |
| Jan 22, 2026 | Ashwath Jayagopal Chief Scientific & Dev. Ofc. | AGrant or award Common Stock | +400,000 | $0.00 | $0 | 525,807 | Jan 26, 2026 |
| Jan 22, 2026 | George Magrath Chief Executive Officer | AGrant or award Common Stock | +483,639 | $0.00 | $0 | 1,775,293 | Jan 26, 2026 |
| Jan 22, 2026 | Joseph K Schachle Chief Operating Officer | AGrant or award Common Stock | +250,000 | $0.00 | $0 | 304,500 | Jan 26, 2026 |
| Jan 22, 2026 | Rabourn Amy Zaremba Head of Fin. Quality Assurance | AGrant or award Common Stock | +86,500 | $0.00 | $0 | 193,128 | Jan 26, 2026 |
| Jan 22, 2026 | Benjamin R Yerxa President | AGrant or award Common Stock | +400,000 | $0.00 | $0 | 719,005 | Jan 26, 2026 |
| Jan 18, 2026 | Rabourn Amy Zaremba Head of Fin. Quality Assurance | FTax withholding Common Stock | -3,390 | $2.10 | $7,119 | 106,628 | Jan 21, 2026 |
| Jan 10, 2026 | Rabourn Amy Zaremba Head of Fin. Quality Assurance | FTax withholding Common Stock | -3,950 | $1.93 | $7,624 | 110,018 | Jan 13, 2026 |
| Jan 6, 2026 | Cam Gallagher director | AGrant or award Common Stock | +67,000 | $0.00 | $0 | 1,991,430 | Jan 8, 2026 |
| Jan 1, 2026 | Sean Ainsworth director | AGrant or award Common Stock | +42,507 | - | - | 297,325 | Jan 5, 2026 |
| Jan 1, 2026 | Jean Bennett director | AGrant or award Common Stock | +21,127 | - | - | 234,652 | Jan 5, 2026 |
| Jan 1, 2026 | Adrienne L Graves director | AGrant or award Common Stock | +23,643 | - | - | 103,147 | Jan 5, 2026 |
| Jan 1, 2026 | James S J Manuso director | AGrant or award Common Stock | +31,188 | - | - | 292,951 | Jan 5, 2026 |
| Dec 29, 2025 | Cam Gallagher director | POpen-market purchase Common Stock | +81,000 | $1.98 | $160k | 1,891,430 | Dec 31, 2025 |
| Dec 29, 2025 | Cam Gallagher director | POpen-market purchase Common Stockindirect: By Garret Gallagher - Custodian UTMA/UGMA | +83,000 | $1.97 | $163k | 83,000 | Dec 31, 2025 |
| Dec 31, 2025 | Cam Gallagher director | AGrant or award Common Stock | +33,000 | $0.00 | $0 | 1,924,430 | Dec 31, 2025 |
| Dec 9, 2025 | Foundation Fighting Blindness Retinal Degeneration Fund director, other | SOpen-market sale Common Stock | -4,000,000 | $2.15 | $8.6M | 5,492,171 | Dec 11, 2025 |
| Nov 1, 2025 | George Magrath Chief Executive Officer | FTax withholding Common Stock | -30,350 | $2.30 | $70k | 1,291,654 | Nov 5, 2025 |
| Nov 1, 2025 | George Magrath Chief Executive Officer | FTax withholding Common Stock | -30,350 | $2.30 | $70k | 1,291,654 | Nov 4, 2025 |
| Oct 22, 2025 | Benjamin R Yerxa President | FTax withholding Common Stock | -23,795 | $1.95 | $46k | 319,005 | Oct 24, 2025 |
| Sep 10, 2025 | Robert E. Gagnon Chief Financial Officer | AGrant or award Common Stock | +200,000 | $0.00 | $0 | 200,000 | Sep 11, 2025 |
| Sep 2, 2025 | Robert E. Gagnon Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Sep 11, 2025 |
| Aug 25, 2025 | Sean Ainsworth director | AGrant or award Common Stock | +86,956 | $1.15 | $100k | 254,818 | Aug 27, 2025 |
| Aug 25, 2025 | Cam Gallagher director | AGrant or award Common Stock | +869,565 | $1.15 | $1000k | 1,810,430 | Aug 27, 2025 |
| May 5, 2025 | Foundation Fighting Blindness Retinal Degeneration Fund director, owner, other | CConversion Common Stock | +6,927,419 | - | - | 9,492,171 | May 6, 2025 |
| May 5, 2025 | Foundation Fighting Blindness Retinal Degeneration Fund director, owner, other | CConversion Series A Non-Voting Convertible Preferred Stockderivative | -6,927 | - | - | 0 | May 6, 2025 |
| Apr 30, 2025 | Jean Bennett director | AGrant or award Common Stock | +79,504 | $0.00 | $0 | 213,525 | May 2, 2025 |
| Apr 30, 2025 | Sean Ainsworth director | AGrant or award Common Stock | +79,504 | $0.00 | $0 | 167,862 | May 2, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Sean Ainsworthdirector
- Jean Bennettdirector
- Susan Bentondirector
- Foundation Fighting Blindness Retinal Degeneration Funddirector, other, owner
- Robert E. GagnonChief Financial Officer
- Cam Gallagherdirector
- Adrienne L Gravesdirector
- Ashwath JayagopalChief Scientific & Dev. Ofc.
- James S J Manusodirector
- George MagrathChief Executive Officer
- Joseph K SchachleChief Operating Officer
- Benjamin R YerxaPresident
- Rabourn Amy ZarembaHead of Fin. Quality Assurance
Questions about IRD
Answered from the filings on this page, as of the latest one.
Are insiders buying IRD?
As of Oct 2, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 2 open-market sells worth $2.9M by 2 insiders at Opus Genetics, Inc. in the last 90 days, net -$2.9M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade IRD on the open market?
Foundation Fighting Blindness Retinal Degeneration Fund (director) sold $2.8M of IRD on Sep 30, 2026 and filed the Form 4 on Oct 2, 2026. InsiderTell scored 45 (moderate).
How many insiders file Form 4 at Opus Genetics, Inc.?
13 people have filed a Form 4 at Opus Genetics, Inc., among them Sean Ainsworth (director), Jean Bennett (director), Susan Benton (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.